Exicure (XCUR) said late Thursday it received a patent in Australia covering its combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx.
The patent supports the company's ongoing phase 2 clinical trial assessing the combination of GPC-100 and propranolol to treat multiple myeloma, a cancer of plasma cells.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。